Skip to content
Vensana

Vensana

  • Our Team
  • Values
  • Our Entrepreneurs

Author: Steve Schwen

Portfolio News

SpyGlass Ophthalmics Completes $27.5 Million Series B Financing to Advance Novel Treatments for Chronic Ophthalmic Diseases

Portfolio News

Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure

Portfolio News

Philips to expand its image-guided therapy devices portfolio through acquisition of Intact Vascular

Portfolio News

CVRx® Raises $50 Million in New Equity Financing

Events

Klein to speak at Life Sciences Future – MedTech

Vensana in the News

Eight VCs Join NVCA Board and Barry Eggers of Lightspeed Appointed Chair

Portfolio News

GPB Scientific Announces $25.5 Million Financing from Vensana Capital and Amgen Ventures

Vensana in the News

Vensana—Is Medtech Investing on the Rebound?

17

Novel FDA PMA & de novo 510k approvals

37

U.S. Commercial Product Launches

34

Level I Clinical Trials

23

Strategic Financings

25

Exits by IPO or M&A

VENSANA CAPITAL

CAPITAL PARTNERS FOR HEALTHCARE ENTREPRENEURS℠

Ready to change healthcare together?

Get in Touch

Our Latest

See All News
SpyGlass Ophthalmics Completes $27.5 Million Series B Financing to Advance Novel Treatments for Chronic Ophthalmic Diseases
Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure
Philips to expand its image-guided therapy devices portfolio through acquisition of Intact Vascular
Resources
News LP Access
Contact
info@vensanacap.com 612.217.8680
Engage
Minneapolis
Vensana Capital 3601 W 76th Street Suite 20 Minneapolis, MN 55435
Washington, D.C.
Vensana Capital 101 Church Street Suite D Vienna, VA 22180

© 2019 Vensana Capital Management, LLC | Privacy | Terms & Conditions